By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion disclosed today a settlement agreement that will provide the company with $1 million.

It also said that its stock has been moved to the Nasdaq Capital Market effective Feb. 15.

In a document filed with the US Securities and Exchange Commission, the Austin, Texas-based molecular diagnostics firm said it has settled with an unnamed third party over Vermillion's losses on short- and long-term investments in previous years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.